作者
Ravi S Hira, Sreekanth Vemulapalli, Zhuokai Li, James M McCabe, John S Rumsfeld, Samir R Kapadia, Mahboob Alam, Hani Jneid, Creighton Don, Mark Reisman, Salim S Virani, Neal S Kleiman
发表日期
2017/8/1
期刊
JAMA cardiology
卷号
2
期号
8
页码范围
846-854
出版商
American Medical Association
简介
Importance
Transcatheter aortic valve replacement (TAVR) was approved by the US Food and Drug Administration for severe aortic stenosis in patients who cannot undergo surgery and for patients at high operative risk. Use of TAVR for off-label indications has not been previously reported.
Objective
To evaluate patterns and adverse outcomes of off-label use of TAVR in US clinical practice.
Design, Setting and Participants
Patients receiving commercially funded TAVR in the United States are included in the Transcatheter Valve Therapy Registry. A total of 23 847 patients from 328 sites performing TAVR between November 9, 2011, and September 30, 2014, were assessed for this study. Off-label TAVR was defined as TAVR in patients with known bicuspid valve, moderate aortic stenosis, severe mitral regurgitation, severe aortic regurgitation, or subaortic stenosis. Data were linked with the Centers for Medicare & …
学术搜索中的文章
RS Hira, S Vemulapalli, Z Li, JM McCabe, JS Rumsfeld… - JAMA cardiology, 2017